MTM(SH:688029) Zheng Quan Zhi Xing·2025-05-13 11:13Core Viewpoint - The annual general meeting of Nanwei Medical Technology Co., Ltd. is set to discuss various proposals, including the confirmation of director and supervisor remuneration for 2024 and 2025, as well as the financial reports and budget for 2025 [1][2][3]. Meeting Procedures - The meeting will ensure the verification of attendees' identities and maintain order to protect shareholders' rights [2][3]. - Attendees must register before the meeting starts, and the meeting will follow a predetermined agenda for discussion and voting on proposals [2][3][4]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the conduct of discussions and questions [2][3][4]. Proposals Overview - Proposal 1: Review of the 2024 Board of Directors' Work Report, which summarizes the previous year's activities and outlines priorities for 2025 [6]. - Proposal 2: Review of the 2024 Supervisory Board's Work Report, detailing the past year's work and future focus [8]. - Proposal 3: Review of the 2024 Financial Settlement Report, which includes a provision for credit and asset impairment totaling approximately 62.41 million yuan [8][9]. - Proposal 4: Review of the 2025 Financial Budget Report, projecting revenue of approximately 3.258 billion yuan, representing an 18% increase [10]. - Proposal 5: Review of the 2024 Annual Report and Summary, which has been approved by the Board [10][11]. - Proposal 6: Review of the 2024 Profit Distribution Plan, proposing a cash dividend distribution based on the total share capital [11][12]. - Proposal 7: Confirmation of the remuneration plan for directors and supervisors for 2024 and 2025, detailing specific amounts for independent directors and performance bonuses for the chairman [13][15]. Financial and Operational Highlights - The company plans to apply for a comprehensive credit limit of up to 1.2 billion yuan from commercial banks to support daily operations and reduce financing costs [16]. - The company has reported a total distributable profit of approximately 1.54 billion yuan as of December 31, 2024, with a proposed cash dividend distribution of 186.94 million yuan [12][13]. Independent Director's Report - The independent director's report emphasizes adherence to legal regulations and the importance of maintaining independence while fulfilling responsibilities [18][32]. - The independent director has actively participated in board meetings and committees, ensuring compliance and effective decision-making [21][35].